Entyvio®
Drug class
- Biologic/biosimilar
- Integrin receptor angonist
Generic name
Vedolizumab
Safety
Efficacy
Convenience
Indications
Approved for moderate to severe Crohn's disease and moderate to severe ulcerative colitis
How it works
By inhibiting specific proteins that cause inflammation, biologic medications reduce disease activity and severity.
Drug interactions
Natalizumab, natalizumab-sztn. TNF-α inhibitors or other immunosuppressants. Corticosteroid medicine.
Pre-treatment screening tests
Hepatitis B panel, tuberculosis infection, and liver function panel.
Tests during screening
Vital signs, signs of infection, especially respiratory or nasal, and impaired liver function.
Payment options
https://www.entyvio.com/copay-supportRoute of administration
Frequency
IV infusion: every 8 weeks Subcutaneous injection: every 2 weeks
Side effects
Upper respiratory infections (flu or colds), joint pain, high liver enzymes, injection or infusion site reaction.
Contraindications
Serious or severe hypersensitivity to vedolizumab or any component of the formulation.
Safety information
Chills, fevers, and joint pain.